Reviva to Participate in the A.G.P. Healthcare Company Showcase

Rhea-AI Summary

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming A.G.P. Healthcare Company Showcase. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the virtual event scheduled for May 21, 2025, at 2:00 p.m. EST.

News Market Reaction – RVPH

+7.40%

+7.40% Session move

In the trading session that priced this news, RVPH gained 7.40%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the A.G.P. Healthcare Company Showcase, taking place virtually May 21, 2025.

A.G.P. Healthcare Company Showcase
Format: Fireside Chat
Date: Wednesday, May 21, 2025
Time: 2:00 p.m. EST
Location: Virtual
Webcast Link: Click Here

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When is Reviva Pharmaceuticals (RVPH) presenting at the A.G.P. Healthcare Company Showcase?

Reviva Pharmaceuticals will present at the A.G.P. Healthcare Company Showcase on Wednesday, May 21, 2025, at 2:00 p.m. EST in a virtual fireside chat format.

Who will represent RVPH at the A.G.P. Healthcare Company Showcase 2025?

Laxminarayan Bhat, Ph.D., who is the Founder, President, and CEO of Reviva Pharmaceuticals, will represent the company at the showcase.

What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?

Reviva Pharmaceuticals focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.

Is the A.G.P. Healthcare Company Showcase 2025 an in-person or virtual event?

The A.G.P. Healthcare Company Showcase 2025 is being held virtually.